GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Short Percentage of Float

Sutro Biopharma (FRA:S09) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Sutro Biopharma's Short Percentage of Float

For the Biotechnology subindustry, Sutro Biopharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sutro Biopharma's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Short Percentage of Float falls into.


Sutro Biopharma (FRA:S09) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Short Percentage of Float
Comparable Companies
ZVRA VSTM APLT STOK GLUE ALLK AKBA LYRA ATNM CYDY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
STRO:USA S09:Germany
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Website
https://www.sutrobio.com
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma (FRA:S09) Headlines

No Headlines